Advertisement

Topics

Companies Related to "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal" [Most Relevant Company Matches] RSS

23:51 EDT 16th October 2018 | BioPortfolio

Here are the most relevant search results for "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal" found in our extensive corporate database of over 50,000 company records.

Showing "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal" Companies 1–25 of 1,100+

Relevant

Quentis Therapeutics

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on our deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, we are pioneering first-in-class ER stress response modulators t...


Quentis Therapeutics Inc.

Quentis Therapeutics is a preclinical stage biotechnology company that is pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer. Based on our deep expertise in ER stress biology and the tumor microenvironment, we are pioneering the use of ER stress response modulators to boost the i...

Presage Biosciences

Presage Biosciences is an oncology company pioneering the incorporation of human efficacy data much earlier in the drug development and clinical trial processes with its patented CIVO arrayed microinjection platform. The CIVO platform allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a ...


Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

Mitra Biotech Inc.

Mitra Biotech, with labs in India and the U.S., is engaged in enabling personalized cancer care and rational drug development through its proprietary pre-clinical platform called CANScriptTM. CANScriptTM is a multi-dimensional platform that can recreate the human tumor microenvironment while maintaining patient tumor heterogeneity, signaling networks and t...

TP Therapeutics, Inc.

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company founded in October 2013 by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drug crizotinib. TP Team is focusing on the design and development of novel chemical identities for established oncogene drivers with high incidence of secondary resistant mutations, ...

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance

Partikula LLC

Partikula is a preclinical stage biotechnology company focused on developing novel therapies for cancer and other diseases based on platform chemistry technologies, including its first-in-class precision Tumor Microenvironment Modifiers (TMEM™), that are designed to deliver therapeutics to the mitochondria and other intracellular targets. Partikula wa...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

Intellikine, Inc.

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseas...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...

AdnaGen AG

AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease. AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and v...

Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

Deciphera Pharmaceuticals, Inc.,

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known t...

Northern Biologics Inc.

Northern Biologics was launched in June 2014 from Blueline Bioscience, a Canadian biotechnology incubator operated by venture capital firm Versant Ventures, in partnership with the University of Toronto and University Health Network’s Princess Margaret Cancer Centre. Headquartered in the MaRS Discovery District of Toronto, the company is developing a ...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Oncomatrix

Oncomatrix is focused on the development of new biopharmaceuticals targeting the tumor stroma. This innovative approach aims not to attack the tumor cells directly but rather the cells supporting the growth and invasiveness of the tumor.

National Brain Tumor Society (NBTS)

National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocati...

Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, such as in an artery, to treat at the source of the disease internally....

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

Paratek Pharmaceuticals Incorporated

Paratek's mission is to overcome the major worldwide problem of bacterial resistance through the application of new proprietary technology and through the development of new antibiotics. Paratek has established two product development programs to identify and develop new pharmaceuticals for the treatment of infectious diseases:The Tetracycline Resistance Project ("Tet Project") based on expertise ...

Surgica Corporation

Surgica Corporation manufactures and markets embolization medical devices for the rapidly growing minimally invasive surgical and therapeutic specialties. Embolization is a minimally invasive procedure that can reduce tumors and vascular malformations by closing off the blood vessels that feed them.The procedure is performed by an interventional radiologist, who advances a catheter through the vas...

Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for

Canyon Pharmaceuticals

Canyon PharmaceuticalsTM is a privately-held specialty biopharmaceuticals company focused on delivering innovative therapeutic solutions that target important cellular pathways in thrombosis and tumor growth. Canyon holds exclusive world-wide rights to desirudin, a subcutaneous (SC) recombinant direct thrombin inhibitor (DTI), and to pegmusirudin, a pegyla...


More From BioPortfolio on "Tumor microenvironment confers mTOR inhibitor resistance invasive intestinal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks